The University of Texas System

Abbvie Inc.

Gene Techno Science Co., Ltd.

Massachusetts Institute of Technology

The Trustees of Boston College

Abbott Laboratories Corporation

National Cheng-Kung University

Kaken Pharmaceutical Company, Ltd.

Chiome Bioscience Inc.

Progenics Pharmaceuticals, Inc.

Arius Research, Inc.

Pdl Biopharma, Inc.

Jn Biosciences LLC

Livtech, Inc.

Abbvie Bahamas Limited

Shankar Kumar

Naoya Tsurushita

J Yun Tso

Paul Robert Hinton

Richard W Dixon

Jonathan P Belk

Yong-Jun Liu

Kui Shin Voo

Laura Bover

Yan Chen

Chengbin Wu

Maria A Argiriadi

Hua Ying

Carolyn A Cuff

Terry L Melim

Koji Nakamura

Zhifeng Ren

Gang Paul Chen

Hiroyuki Yanai

Toru Kanke

Ming-Shi Chang

Michael Roguska

Nicholas F Landolfi

Mildred S Dresselhaus

Kentaro Okamura

Shigeyuki Kon

Emma Fung

Susan E Lacy

Bed Poudel

Maki Tamura

Wenzhong Wang

William C Olson

David S F Young

Susan E Hahn

Helen P Findlay

Dangshe Ma

Martin R Jefson

Toshimitsu Uede

Daad Sayegh

Gerald P Donovan

Tatsuhiro Harada

Michael K Ahlijanian

Luis A G Da Cruz

Albert Cupo

Rie Tajima

Brian Kennedy

Yun Kang

Andre J Marozsan

Hohyun Lee

Kristian Rogers

Kirsten Nagashima

The present disclosure relates generally to conformation-specific antibodies that can bind to and neutralize the activity of phosphorylated-Threonine 231-tau protein (pT231-tau). The antibodies of the present technology are useful in methods for treating a neurological disorder associated with elevated cis-pT231-tau protein expression in a subject in need thereof.

Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies

The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.

Interleukin-13 binding proteins

Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

Anti-OX40 antibodies and methods of using the same

The present invention provides: an antibody which specifically reacts with hTROP-2 and has anti-tumor activity in vivo (particularly, a humanized antibody); a hybridoma which produces the aforementioned antibody; a conjugate of the aforementioned antibody and a drug; a pharmaceutical composition for diagnosing or treating a tumor; a method for detecting a tumor; and a kit for detecting or diagnosing a tumor.

Anti-human TROP-2 antibody having an antitumor activity in vivo

Humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.

Humanized anti-IL-20 antibody and uses thereof

Nucleic acid encoding anti-OX40 antibodies

The present invention provides: antibodies specifically reacting against hDlk-1 and having anti-tumor activity in vivo (anti-hDlk-1 antibodies, and in particular, humanized anti-hDlk-1 antibodies); fragments of the antibodies; hybridomas that produce the antibodies; a complex of the antibody or antibody fragment and an agent; a pharmaceutical composition, a tumor therapeutic agent, a tumor diagnostic agent and an agent for inducing apoptosis in tumor cells, each of which comprises the aforementioned antibody or the like; a method for treating tumor, a method for detecting tumor, a method for inducing apoptosis in tumor cells, a kit for detecting and/or diagnosing tumor and a kit for inducing apoptosis in tumor cells, each of which comprises the use of the aforementioned antibody or the like; etc.

Anti-hDlk-1 antibody having an antitumor activity in vivo

Anti-OX40 antibodies and methods of treating cancer

The invention provides monoclonal antibodies that specifically bind to CD122, which is one component of receptors for IL-2 and IL-15. The monoclonal antibodies have the capacity for substantial inhibition of both IL-2 and IL-15 mediated functions by inhibiting binding of these cytokines to their receptors. The monoclonal antibodies can be used for inhibiting undesired immune responses or treatment of cancer, among other applications.

Antibodies to CD122

Growing community of inventors

Pleasanton, CA, United States of America

Shankar Kumar